• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Case Report: Calcium sensing receptor gene gain of function mutations: a case series and report of 2 novel mutations.病例报告:钙敏感受体基因功能获得性突变:病例系列及 2 种新突变的报告。
Front Endocrinol (Lausanne). 2023 Aug 15;14:1215036. doi: 10.3389/fendo.2023.1215036. eCollection 2023.
2
Identification of p.Arg205Cys in CASR in an autosomal dominant hypocalcaemia type 1 pedigree: A case report.1型常染色体显性低钙血症家系中钙敏感受体(CASR)基因p.Arg205Cys突变的鉴定:一例报告
Medicine (Baltimore). 2021 Jun 25;100(25):e26443. doi: 10.1097/MD.0000000000026443.
3
Activating Mutations of the G-protein Subunit α 11 Interdomain Interface Cause Autosomal Dominant Hypocalcemia Type 2.G 蛋白亚基α11 结构域间界面的激活突变导致常染色体显性低钙血症 2 型。
J Clin Endocrinol Metab. 2020 Mar 1;105(3):952-63. doi: 10.1210/clinem/dgz251.
4
Differential parathyroid and kidney Ca-sensing receptor activation in autosomal dominant hypocalcemia 1.常染色体显性低钙血症 1 中甲状旁腺和肾脏钙敏感受体的差异激活。
EBioMedicine. 2022 Apr;78:103947. doi: 10.1016/j.ebiom.2022.103947. Epub 2022 Mar 18.
5
Autosomal dominant hypocalcemia with a novel mutation: a case study and literature review.常染色体显性低钙血症伴新突变:病例研究与文献回顾。
J Int Med Res. 2022 Jul;50(7):3000605221110489. doi: 10.1177/03000605221110489.
6
Identification of a G-Protein Subunit-α11 Gain-of-Function Mutation, Val340Met, in a Family With Autosomal Dominant Hypocalcemia Type 2 (ADH2).在一个患有2型常染色体显性低钙血症(ADH2)的家族中鉴定出G蛋白亚基α11功能获得性突变Val340Met。
J Bone Miner Res. 2016 Jun;31(6):1207-14. doi: 10.1002/jbmr.2797.
7
Novel Calcium-Sensing Receptor (CASR) Mutation in a Family with Autosomal Dominant Hypocalcemia Type 1 (ADH1): Genetic Study over Three Generations and Clinical Characteristics.一个常染色体显性低钙血症 1 型(ADH1)家族中的新型钙敏感受体(CASR)突变:三代遗传研究和临床特征。
Horm Res Paediatr. 2023;96(5):473-482. doi: 10.1159/000529833. Epub 2023 Feb 22.
8
Autosomal Dominant Hypocalcemia Type 1: A Systematic Review.常染色体显性低钙血症 1 型:系统评价。
J Bone Miner Res. 2022 Oct;37(10):1926-1935. doi: 10.1002/jbmr.4659. Epub 2022 Aug 22.
9
The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1).钙敏化剂NPS 2143可纠正激活型钙敏感受体(CaSR)突变小鼠模型中的低钙血症:与1型常染色体显性低钙血症(ADH1)的相关性。
Endocrinology. 2015 Sep;156(9):3114-21. doi: 10.1210/en.2015-1269. Epub 2015 Jun 8.
10
Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH).钙敏感受体(CaSR)突变基因敲入小鼠模拟常染色体显性低钙血症(ADH)的异常,钙敏调节剂可改善这些异常。
J Bone Miner Res. 2015 Nov;30(11):1980-93. doi: 10.1002/jbmr.2551. Epub 2015 Jul 16.

引用本文的文献

1
Molecular regulation of calcium-sensing receptor (CaSR)-mediated signaling.钙敏感受体(CaSR)介导信号传导的分子调控
Chronic Dis Transl Med. 2024 Apr 29;10(3):167-194. doi: 10.1002/cdt3.123. eCollection 2024 Sep.

本文引用的文献

1
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.甲状旁腺激素替代治疗甲状旁腺功能减退症的疗效和安全性:第 3 阶段 PaTHway 试验的 26 周结果。
J Bone Miner Res. 2023 Jan;38(1):14-25. doi: 10.1002/jbmr.4726. Epub 2022 Nov 12.
2
Initial Assessment and Monitoring of Patients with Chronic Hypoparathyroidism: A Systematic Current Practice Survey.慢性甲状旁腺功能减退症患者的初始评估和监测:一项系统的当前实践调查。
J Bone Miner Res. 2022 Dec;37(12):2630-2641. doi: 10.1002/jbmr.4698. Epub 2022 Nov 14.
3
Autosomal Dominant Hypocalcemia Type 1: A Systematic Review.常染色体显性低钙血症 1 型:系统评价。
J Bone Miner Res. 2022 Oct;37(10):1926-1935. doi: 10.1002/jbmr.4659. Epub 2022 Aug 22.
4
Autosomal Dominant Hypocalcemia Type 1 (ADH1) Associated With Myoclonus and Intracerebral Calcifications.1型常染色体显性低钙血症(ADH1)伴肌阵挛和脑内钙化
J Endocr Soc. 2022 Mar 18;6(5):bvac042. doi: 10.1210/jendso/bvac042. eCollection 2022 May 1.
5
PTH Infusion for Seizures in Autosomal Dominant Hypocalcemia Type 1.1型常染色体显性低钙血症中甲状旁腺激素输注治疗癫痫发作
N Engl J Med. 2021 Jul 8;385(2):189-191. doi: 10.1056/NEJMc2034981.
6
Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism.基底节钙化与成人甲状旁腺功能减退症的局部和全身代谢机制有关。
J Clin Endocrinol Metab. 2021 Jun 16;106(7):1900-1917. doi: 10.1210/clinem/dgab162.
7
Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare Population.家族性低钙尿性高钙血症 1 型和常染色体显性低钙血症 1 型:在大型医疗保健人群中的患病率。
Am J Hum Genet. 2020 Jun 4;106(6):734-747. doi: 10.1016/j.ajhg.2020.04.006. Epub 2020 May 7.
8
Molecular and clinical insights from studies of calcium-sensing receptor mutations.钙敏感受体突变研究的分子和临床见解。
J Mol Endocrinol. 2019 Aug;63(2):R1-R16. doi: 10.1530/JME-19-0104.
9
Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPSP795 (SHP635).治疗常染色体显性低钙血症 1 型的钙敏感受体激动剂 NPSP795(SHP635)。
J Bone Miner Res. 2019 Sep;34(9):1609-1618. doi: 10.1002/jbmr.3747. Epub 2019 Jul 26.
10
Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus.成人甲状旁腺功能减退症的护理标准:加拿大与国际共识
Eur J Endocrinol. 2019 Mar;180(3):P1-P22. doi: 10.1530/EJE-18-0609.

病例报告:钙敏感受体基因功能获得性突变:病例系列及 2 种新突变的报告。

Case Report: Calcium sensing receptor gene gain of function mutations: a case series and report of 2 novel mutations.

机构信息

Division of Endocrinology and Metabolism, McMaster University, Hamilton, ON, Canada.

Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO) Onlus, Italian Foundation for the Research on Bone Diseases, Florence, Italy.

出版信息

Front Endocrinol (Lausanne). 2023 Aug 15;14:1215036. doi: 10.3389/fendo.2023.1215036. eCollection 2023.

DOI:10.3389/fendo.2023.1215036
PMID:37654565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10466028/
Abstract

Autosomal dominant hypocalcemia (ADH1) is a genetic disorder characterized by low serum calcium and low or inappropriately normal levels of parathyroid hormone. The disease is caused by a heterozygous activating mutation of the calcium-sensing receptor () gene, encoding a G-Protein-coupled cell membrane sensor of extracellular calcium concentration mainly expressed by parathyroid glands, renal tubules, and the brain. ADH1 has been linked to 113 unique germline mutations, of which nearly 96% are missense mutations. There is often a lack of a clear genotype/phenotype correlation in the reported literature. Here, we described a case series of 6 unrelated ADH1 probands, each one bearing a gain-of-function mutation, and two children of one of these cases, matching our identified mutations to the same ones previously reported in the literature, and comparing the clinical and biochemical characteristics, as well as the complication profile. As a result of these genetic and clinical comparisons, we propose that a genotype/phenotype correlation may exist because our cases showed similar presentation, characteristics, and severity, with respect to published cases with the same or similar mutations. We also contend that the severity of the presentation is highly influenced by the specific variant. These findings, however, require further evaluation and assessment with a systematic review.

摘要

常染色体显性低钙血症(ADH1)是一种遗传疾病,其特征为血清钙水平低,甲状旁腺激素水平低或不成比例地正常。该病由钙敏感受体()基因的杂合激活突变引起,该基因编码细胞外钙浓度的 G 蛋白偶联细胞膜传感器,主要在甲状旁腺、肾小管和脑中表达。ADH1 与 113 个独特的种系突变有关,其中近 96%为错义突变。在报告的文献中,通常缺乏明确的基因型/表型相关性。在这里,我们描述了 6 例无关的 ADH1 先证者的病例系列,每个先证者都携带功能获得性突变,以及其中一个病例的两个孩子,将我们鉴定的突变与文献中先前报道的相同突变相匹配,并比较了临床和生化特征以及并发症谱。由于这些遗传和临床比较,我们提出基因型/表型可能存在相关性,因为我们的病例与具有相同或相似突变的已发表病例表现出相似的表现、特征和严重程度。我们还认为,表型的严重程度受特定变异体的高度影响。然而,这些发现需要进一步评估和评估,并进行系统审查。